ArticleThe Journal of allergy and clinical immunology2024
Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma.
Article in The Journal of allergy and clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- COPD Biologics: Right Patient, Right Pathway, Right Time.Pulmonary therapy · 2026Review
- Effectiveness of mepolizumab on mucus plugs and clinical outcomes in severe eosinophilic asthma with and without coexisting bronchiectasis: a prospective pilot study.ERJ open research · 2026Article
- Article
- Eosinophil diversity and function: emerging insights into subtypes and therapeutic targets.Cell death discovery · 2026Review
- Mechanisms of Eosinophil Degranulation.Cells · 2026Review
- Association of Vitamin D Receptor Gene Polymorphisms with Serum 25-Hydroxyvitamin D Levels in Lithuanian Adults with Atopic Dermatitis: A Case-Control Study.International journal of molecular sciences · 2026Article
- Mucus Plugging as a Treatable Trait Across the Asthma-COPD Spectrum: The Role of Type 2 Cytokine Blockade and Quantitative Imaging.Biomedicines · 2026Review
- Article
- Asthma endotypes and theratypes.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Loss of Rab44 attenuates ovalbumin-induced allergic airway inflammation by modulating immune responses and eosinophil function.Frontiers in immunology · 2026Article
- Advancements in diagnosis, preventive care, and future directions in the holistic management of pediatric asthma.Frontiers in pediatrics · 2026Review
- Impact of IL-5 Pathway Inhibition on Circulating Eosinophil- and Remodeling-Related Biomarkers in Severe Eosinophilic Asthma.Journal of asthma and allergy · 2026Article
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Eosinophils in lung cancer: from inflammatory cytokines to immunotherapeutic biomarkers.Frontiers in immunology · 2026Review
- Long-Term Administration of BTH2 Hypoallergenic Vaccine Candidate Induces Hallmarks of Allergen Immunotherapy in Murine Model ofBiomedicines · 2025Article
- Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review.Journal of personalized medicine · 2025Review
- The immunology of asthma.Nature immunology · 2025Review
- Spatial Eosinophil Phenotypes as Immunopathogenic Determinants in Inflammatory Diseases.Cells · 2025Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 12 institutions in 2 countries.
Funding
Abstract
backgroundThe relative utility of eosinophil peroxidase (EPX) and blood and sputum eosinophil counts as disease biomarkers in asthma is uncertain.
objectiveWe sought to determine the utility of EPX as a biomarker of systemic and airway eosinophilic inflammation in asthma.
methodsEPX protein was measured by immunoassay in serum and sputum in 110 healthy controls to establish a normal reference range and in repeated samples of serum and sputum collected during 3 years of observation in 480 participants in the Severe Asthma Research Program 3.
resultsOver 3 years, EPX levels in patients with asthma were higher than normal in 27% to 31% of serum samples and 36% to 53% of sputum samples. Eosinophils and EPX correlated better in blood than in sputum (r
conclusionsSerum EPX is a valid protein biomarker of systemic eosinophilic inflammation in asthma, and sputum EPX levels are a more sensitive biomarker of airway eosinophilic inflammation than sputum eosinophil counts. Eosinophil measures in blood frequently miss airway eosinophilic inflammation, and mepolizumab frequently fails to normalize airway eosinophilic inflammation even though it invariably normalizes systemic eosinophilic inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.